Back to Search Start Over

Identification of LRP-1 as an endocytosis and recycling receptor for β1-integrin in thyroid cancer cells.

Authors :
Theret L
Jeanne A
Langlois B
Hachet C
David M
Khrestchatisky M
Devy J
Hervé E
Almagro S
Dedieu S
Source :
Oncotarget [Oncotarget] 2017 Aug 10; Vol. 8 (45), pp. 78614-78632. Date of Electronic Publication: 2017 Aug 10 (Print Publication: 2017).
Publication Year :
2017

Abstract

LRP-1 is a large endocytic receptor mediating the clearance of various molecules from the extracellular matrix. LRP-1 was reported to control focal adhesion turnover to optimize the adhesion-deadhesion balance to support invasion. To better understand how LRP-1 coordinates cell-extracellular matrix interface, we explored its ability to regulate cell surface integrins in thyroid carcinomas. Using an antibody approach, we demonstrated that β1-integrin levels were increased at the plasma membrane under LRP1 silencing or upon RAP treatment, used as LRP-1 antagonist. Our data revealed that LRP-1 binds with both inactive and active β1-integrin conformations and identified the extracellular ligand-binding domains II or IV of LRP-1 as sufficient to bind β1-integrin. Using a recombinant β1-integrin, we demonstrated that LRP-1 acts as a regulator of β1-integrin intracellular traffic. Moreover, RAP or LRP-1 blocking antibodies decreased up to 36% the number of β1-integrin-containing endosomes. LRP-1 blockade did not significantly affect the levels of β1-integrin-containing lysosomes while decreasing localization of β1-integrin within Rab-11 positive vesicles. Overall, we identified an original molecular process in which LRP-1 acts as a main regulator of β1-integrin internalization and recycling in thyroid cancer cells.<br />Competing Interests: CONFLICTS OF INTEREST The authors declare no conflicts of interest.

Details

Language :
English
ISSN :
1949-2553
Volume :
8
Issue :
45
Database :
MEDLINE
Journal :
Oncotarget
Publication Type :
Academic Journal
Accession number :
29108253
Full Text :
https://doi.org/10.18632/oncotarget.20201